Charcot-Marie-Tooth disease (CMT) is the most common inherited disorder of the peripheral nervous system. Mutations in the 27-kDa small heat-shock protein gene (HSPB1) cause axonal CMT or distal hereditary motor neuropathy (distal HMN). We developed and characterized transgenic mice expressing two different HSPB1 mutations (S135F and P182L) in neurons only. These mice showed all features of CMT or distal HMN dependent on the mutation. Expression of mutant HSPB1 decreased acetylated α-tubulin abundance and induced severe axonal transport deficits. An increase of α-tubulin acetylation induced by pharmacological inhibition of histone deacetylase 6 (HDAC6) corrected the axonal transport defects caused by HSPB1 mutations and rescued the CMT phenotype of symptomatic mutant HSPB1 mice. Our findings demonstrate the pathogenic role of α-tubulin deacetylation in mutant HSPB1–induced neuropathies and offer perspectives for using HDAC6 inhibitors as a therapeutic strategy for hereditary axonopathies.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Barisic, N. et al. Charcot-Marie-Tooth disease: a clinico-genetic confrontation. Ann. Hum. Genet. 72, 416–441 (2008).
Züchner, S. & Vance, J.M. Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat. Clin. Pract. Neurol. 2, 45–53 (2006).
Ismailov, S.M. et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur. J. Hum. Genet. 9, 646–650 (2001).
Evgrafov, O.V. et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat. Genet. 36, 602–606 (2004).
Arrigo, A.P. The cellular “networking” of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis. Adv. Exp. Med. Biol. 594, 14–26 (2007).
Dierick, I., Irobi, J., de Jonghe, P. & Timmerman, V. Small heat shock proteins in inherited peripheral neuropathies. Ann. Med. 37, 413–422 (2005).
Xanthoudakis, S. & Nicholson, D. Heat-shock proteins as death determinants. Nat. Cell Biol. 2, E163–E165 (2000).
Houlden, H. et al. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 71, 1660–1668 (2008).
Ikeda, Y. et al. A clinical phenotype of distal hereditary motor neuronopathy type II with a novel HSPB1 mutation. J. Neurol. Sci. 277, 9–12 (2009).
James, P.A., Rankin, J. & Talbot, K. Asymmetrical late onset motor neuropathy associated with a novel mutation in the small heat shock protein HSPB1 (HSP27). J. Neurol. Neurosurg. Psychiatry 79, 461–463 (2008).
Kijima, K. et al. Small heat shock protein 27 mutation in a Japanese patient with distal hereditary motor neuropathy. J. Hum. Genet. 50, 473–476 (2005).
Ackerley, S. et al. A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. Hum. Mol. Genet. 15, 347–354 (2006).
Zhai, J., Lin, H., Julien, J. & Schlaepfer, W.W. Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease–linked mutations in NFL and HSPB1. Hum. Mol. Genet. 16, 3103–3116 (2007).
Aigner, L. et al. Overexpression of the neural growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice. Cell 83, 269–278 (1995).
Caroni, P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J. Neurosci. Methods 71, 3–9 (1997).
Michailov, G.V. et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304, 700–703 (2004).
Hamers, F.P.T., Koopmans, G.C. & Joosten, E.A.J. CatWalk-assisted gait analysis in the assessment of spinal cord injury. J. Neurotrauma 23, 537–548 (2006).
Vandeputte, C. et al. Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci. 11, 92 (2010).
Hollenbeck, P.J. & Saxton, W.M. The axonal transport of mitochondria. J. Cell Sci. 118, 5411–5419 (2005).
Westermann, S. & Weber, K. Post-translational modifications regulate microtubule function. Nat. Rev. Mol. Cell Biol. 4, 938–947 (2003).
Chen, S., Owens, G.C., Makarenkova, H. & Edelman, D.B. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS ONE 5, e10848 (2010).
Gardiner, J., Barton, D., Marc, J. & Overall, R. Potential role of tubulin acetylation and microtubule-based protein trafficking in familial dysautonomia. Traffic 8, 1145–1149 (2007).
Hempen, B. & Brion, J.P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55, 964–972 (1996).
Hammond, J.W., Cai, D. & Verhey, K.J. Tubulin modifications and their cellular functions. Curr. Opin. Cell Biol. 20, 71–76 (2008).
Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458 (2002).
Zhang, Y. et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22, 1168–1179 (2003).
Haggarty, S.J., Koeller, K.M., Wong, J.C., Grozinger, C.M. & Schreiber, S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100, 4389–4394 (2003).
Butler, K.V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842–10846 (2010).
Dierick, I. et al. Relative contribution of mutations in genes for autosomal dominant distal hereditary motor neuropathies: a genotype-phenotype correlation study. Brain 131, 1217–1227 (2008).
Detmer, S.A., Vande Velde, C., Cleveland, D.W. & Chan, D.C. Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A. Hum. Mol. Genet. 17, 367–375 (2008).
Cartoni, R. et al. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain 133, 1460–1469 (2010).
Dequen, F. et al. Reversal of neuropathy phenotypes in conditional mouse model of Charcot-Marie-Tooth disease type 2E. Hum. Mol. Genet. 19, 2616–2629 (2010).
Huang, L., Min, J., Masters, S., Mivechi, N.F. & Moskophidis, D. Insights into function and regulation of small heat shock protein 25 (HSPB1) in a mouse model with targeted gene disruption. Genesis 45, 487–501 (2007).
Baloh, R.H., Schmidt, R.E., Pestronk, A. & Milbrandt, J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci. 27, 422–430 (2007).
Niemann, A., Ruegg, M., La Padula, V., Schenone, A. & Suter, U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J. Cell Biol. 170, 1067–1078 (2005).
de Brito, O.M. & Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605–610 (2008).
Misko, A., Jiang, S., Wegorzewska, I., Milbrandt, J. & Baloh, R.H. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J. Neurosci. 30, 4232–4240 (2010).
Tradewell, M.L., Durham, H.D., Mushynski, W.E. & Gentil, B.J. Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of Charcot-Marie-Tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion. J. Neuropathol. Exp. Neurol. 68, 642–652 (2009).
De Vos, K.J., Grierson, A.J., Ackerley, S. & Miller, C.C.J. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 31, 151–173 (2008).
Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009).
Friedman, J.R., Webster, B.M., Mastronarde, D.N., Verhey, K.J. & Voeltz, G.K. ER sliding dynamics and ER-mitochondrial contacts occur on acetylated microtubules. J. Cell Biol. 190, 363–375 (2010).
Dompierre, J.P. et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571–3583 (2007).
Chuang, D.M., Leng, Y., Marinova, Z., Kim, H. & Chiu, C. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591–601 (2009).
Kazantsev, A.G. & Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854–868 (2008).
Rivieccio, M.A. et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc. Natl. Acad. Sci. USA 106, 19599–19604 (2009).
Dietz, K.C. & Casaccia, P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res. 62, 11–17 (2010).
Vanden Berghe, P., Hennig, G.W. & Smith, T.K. Characteristics of intermittent mitochondrial transport in guinea pig enteric nerve fibers. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G671–G682 (2004).
We thank L. Almeida-Souza and S. Janssens for their constructive comments and the Molecular Small Animal Imaging Centre (MoSAIC, K.U. Leuven) for the use of the Catwalk system. We are grateful to B. Weynants and N. Hersmus for the technical assistance. We thank R. Mazitschek and J. Bradner (Dana-Farber Cancer Institute, Harvard Medical School) for kindly giving us tubacin. The research to create tubastatin A was supported by an American Chemical Society Fellowship and by the International Rett Syndrome Foundation. We thank J. H. Kalin for helping us with the creation of the HDAC6 homology model. This work was supported by grants from the Fund for Scientific Research Flanders (FWO-Vlaanderen), the University of Leuven (K.U. Leuven, GOA/12/014 and OT/10/046), the Belgian government (Interuniversity Attraction Poles, programme P6/43 of the Belgian Federal Science Policy Office), the Association Belge contre les Maladies neuro-Musculaires, the Association Française contre les Myopathies (projects 13169 and 14471), the Frick Foundation for Amyotrophic Lateral Sclerosis Research, the Muscular Dystrophy Association and the European Community's Health Seventh Framework Programme (FP7/2007-2013 under grant agreement 259867). C.d.Y. is supported by the Agency for Innovation by Science and Technology in Flanders. P.V.D. is a clinical researcher, and J.I. is a postdoctoral fellow of the FWO-Vlaanderen. W.R. is supported through the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders.
The authors declare no competing financial interests.
About this article
Cite this article
d'Ydewalle, C., Krishnan, J., Chiheb, D. et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease. Nat Med 17, 968–974 (2011). https://doi.org/10.1038/nm.2396
A weakened interface in the P182L variant of HSP27 associated with severe Charcot‐Marie‐Tooth neuropathy causes aberrant binding to interacting proteins
The EMBO Journal (2021)
Neuroscience Letters (2021)
Annual Review of Pathology: Mechanisms of Disease (2021)
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors
European Journal of Medicinal Chemistry (2021)